| dc.creator | Laskari K., Boura P., Dalekos G.N., Garyfallos A., Karokis D., Pikazis D., Settas L., Skarantavos G., Tsitsami E., Sfikakis P.P. | en |
| dc.date.accessioned | 2023-01-31T08:48:57Z | |
| dc.date.available | 2023-01-31T08:48:57Z | |
| dc.date.issued | 2015 | |
| dc.identifier | 10.1186/1546-0096-13-S1-P72 | |
| dc.identifier.issn | 15460096 | |
| dc.identifier.uri | http://hdl.handle.net/11615/75697 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | Pediatric Rheumatology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84956745684&doi=10.1186%2f1546-0096-13-S1-P72&partnerID=40&md5=0cb9c30fea76ace5157d446be151c2ee | |
| dc.subject | antibiotic agent | en |
| dc.subject | C reactive protein | en |
| dc.subject | canakinumab | en |
| dc.subject | colchicine | en |
| dc.subject | corticosteroid | en |
| dc.subject | interleukin 1 | en |
| dc.subject | adolescent | en |
| dc.subject | adult | en |
| dc.subject | aged | en |
| dc.subject | Article | en |
| dc.subject | clinical article | en |
| dc.subject | combination chemotherapy | en |
| dc.subject | drug dose reduction | en |
| dc.subject | drug efficacy | en |
| dc.subject | drug response | en |
| dc.subject | drug safety | en |
| dc.subject | drug tolerability | en |
| dc.subject | familial Mediterranean fever | en |
| dc.subject | female | en |
| dc.subject | follow up | en |
| dc.subject | Greek (people) | en |
| dc.subject | human | en |
| dc.subject | male | en |
| dc.subject | monotherapy | en |
| dc.subject | priority journal | en |
| dc.subject | protein blood level | en |
| dc.subject | remission | en |
| dc.subject | retrospective study | en |
| dc.subject | treatment duration | en |
| dc.subject | urinary tract infection | en |
| dc.subject | BioMed Central Ltd. | en |
| dc.title | The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: The Greek experience in 12 patients | en |
| dc.type | journalArticle | en |